ConductScience.org, home

Comparison · NCT02536378-a380bdb2

PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Procedural Success

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Procedural Success. Trial comparisons, record NCT02536378-a380bdb2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02536378-a380bdb2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9970.9890.999wilson
Risk in group 20.9970.990.999wilson
Risk difference, group 1 minus group 2-0.000274-0.008830.00765newcombe hybrid score
Risk ratio, group 1 over group 210.9941.01log
Odds ratio, group 1 over group 20.9130.1286.5log
Number needed to treat, for one fewer participant with the outcome on PP (Per Protocol) than on ITT (Intention to Treat)3,640from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1PP (Per Protocol)
Patients who underwent the study procedure, independent of the success of the procedure and in the absence of major protocol deviations. The analysis of the PP population excludes those subjects for whom a major protocol deviation was identified by the CEC
630632OG000
Group 2ITT (Intention to Treat)All patients who were enrolled in the pivotal phase of the study, including patients with major protocol deviations690692OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Procedural Success
Description
Procedural success is defined as acute device success (successful insertion of the ENROUTE NPS and establishment of flow reversal), technical success (deployment of interventional tools) and the absence of a major adverse events (hierarchical stroke/death/myocardial infarction) through 30 days.
Time frame
30 Days
Population

Source ClinicalTrials.gov

Trial

Title
POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE
NCT number
NCT02536378
Phases
Conditions
Carotid Artery Disease
Interventions
Lead sponsor
Silk Road Medical
Results first posted
2020-07-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02536378-a380bdb2